Comparison of the Structure and Function of the Retina and the Optic Nerve in Patients with a History of Multiple Sclerosis-Related Demyelinating Retrobulbar Optic Neuritis Treated and Not Treated with Systemic Steroid Therapy
Barbara Nowacka,Wojciech Lubiński
DOI: https://doi.org/10.2147/OPTH.S309975
2021-06-01
Clinical Ophthalmology
Abstract:Barbara Nowacka, Wojciech Lubiński 2nd Department of Ophthalmology, Pomeranian Medical University, Szczecin, Poland Correspondence: Wojciech Lubiński 2nd Department of Ophthalmology, Pomeranian Medical University, Powstańców Wlkp. 72, Szczecin, 70-111, Poland Tel +48 91 466 12 93 Email Purpose: To compare the structure and function of the retina and the optic nerve in patients with a history of multiple sclerosis (MS)-related demyelinating retrobulbar optic neuritis treated and not treated with systemic steroid therapy. Patients and Methods: Thirty-two eyes of 32 MS patients with a past single episode of MS-related demyelinating retrobulbar ON were divided into 2 groups: S(+) consisting of 16 patients treated with intravenous methylprednisolone at a dose of 1g/day for 3 days during the acute stage of ON and S(-) consisting of 16 patients who did not receive any treatment. The following examinations were performed: distance best-corrected visual acuity (DBCVA) (Snellen), slit-lamp examination of the anterior and posterior segment of the eye (90D Volk lens), visual field analysis (Carl Zeiss Humphrey 750 Visual Field Analyzer, 24-2, W-W), macular thickness in the foveal (RT1) and parafoveal region (RT2), as well as peripapillary retinal nerve fiber layer thickness (RNFL) in the temporal, superior, nasal and inferior quadrants (Carl Zeiss Cirrus HD-OCT), assessment of the bioelectrical function of the visual pathway with an emphasis on the optic nerve – pattern visual evoked potentials (PVEP) and of macular ganglion cells and cone photoreceptors – pattern electroretinogram (PERG) (Roland Consult). Results: No statistically significant differences were observed between the investigated groups in terms of DBCVA, mean deviation of visual field macular (RT1, RT2) and RNFL thickness in the temporal, superior, nasal and inferior quadrants, as well as of the bioelectrical function (PVEP, PERG). Conclusion: The application of steroid therapy should be considered on an individual basis and not as a routine treatment for each patient. Keywords: demyelinating optic neuritis, multiple sclerosis, steroids, perimetry, OCT, PERG, PVEP Demyelinating retrobulbar optic neuritis (ON) is an inflammatory condition that typically causes acute unilateral vision loss, relative afferent pupillary defect and pain with eye movement, with normal fundus examination. It is closely linked to multiple sclerosis (MS) and may be the first manifestation of this systemic disease. The pathogenesis of MS-related demyelinating ON is not well understood. It is probably caused by delayed type IV hypersensitivity reaction induced by activated peripheral T-cells which release cytokines and other inflammatory mediators. 1 , 2 Permanent visual deficit in demyelinating ON is a result of axonal loss in the optic nerve and retina and a conduction block caused by the demyelination of the optic nerve. 3 , 4 Initially, the result of the Optic Neuritis Treatment Trial (ONTT) showed that the final values of visual acuity and visual field recovery do not dependent on steroid treatment; however, intravenous methylprednisolone administration (1 g per day for 3 days), followed by oral prednisone (1 mg per kilogram per day for 11 days) improves the speed of recovery. 5 , 6 Oral prednisone alone was an ineffective treatment and increased the risk of new episodes of optic neuritis. 6 The effectiveness of steroids in the treatment of MS-related demyelinating ON was investigated in later studies. The results were concluded in the meta-analysis demonstrating that the comparison of treatment with intravenous methylprednisolone alone and placebo revealed no superiority in terms of visual acuity and contrast sensitivity at six months and at one year. 7 Currently, treatment with 1 g intravenous methylprednisolone for 3 days is recommended only to patients with severe or bilateral vision loss to increase the speed of visual recovery, or to patients with two or more white matter lesions on magnetic resonance imaging (MRI) in order to reduce the risk of conversion to MS within the first two years. 6–8 However, many ophthalmologists and neurologists still routinely treat MS-related demyelinating ON with intravenous methylprednisolone. As treatment with steroids is not free from side effects (most common include mood changes, facial flushing, sleep disturbances, weight gain, dyspepsia), 6 we decided to compare long-term visual, structural and bioelectrical outcome fr -Abstract Truncated-